MIR4773-2: A Drug Target / Disease Biomarker (G100616418)
MIR4773-2: A Drug Target / Disease Biomarker
MIR4773-2 is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the MIR family of RNA-binding proteins, which are known for their ability to interact with small RNA species. In recent years, researchers have been interested in studying the function of MIR4773-2 in various biological processes, including cancer, neurodegenerative diseases, and autoimmune disorders.
One of the key reasons why MIR4773-2 has generated so much interest is its potential as a drug target. Several studies have shown that MIR4773-2 can interact with various small RNA species, including microRNAs (miRNAs) and short non-coding RNAs (snRNAs). These interactions can alter the expression of downstream genes, potentially leading to the regulation of various cellular processes.
In addition to its potential as a drug target, MIR4773-2 has also been shown to be a valuable biomarker for various diseases. For example, several studies have shown that MIR4773-2 is downregulated in various cancer tissues, including breast cancer, lung cancer, and colon cancer. This suggests that MIR4773-2 may be a useful target for cancer therapies that aim to increase the expression of this protein.
Another potential application of MIR4773-2 is its role in neurodegenerative diseases. Several studies have shown that MIR4773-2 is involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These findings suggest that MIR4773-2 may be a useful target for therapies aimed at treating these conditions.
In addition to its potential applications as a drug target and biomarker, MIR4773-2 has also generated interest due to its unique structure and biochemical properties. MIR4773-2 is a 21-kDa protein that consists of a unique N-terminal region that contains a conserved nucleotide sequence. This region is known as the N-terminal alpha-helicase domain, which is responsible for the protein's ability to interact with small RNA species.
The N-terminal alpha-helicase domain is made up of 13 amino acids and is located at the beginning of the protein. It consists of a nucleotide sequence that is highly conserved across various species, including humans. This conservation suggests that the N-terminal alpha-helicase domain may be a key factor in the protein's function and stability.
In addition to its unique structure, MIR4773-2 has also generated interest due to its ability to interact with various small RNA species. This interaction is mediated by the N-terminal alpha-helicase domain, which contains a conserved nucleotide sequence that is known as the alpha-helicase domain. This domain is responsible for the protein's ability to recognize and bind to small RNA species, including miRNAs and snRNAs.
Several studies have shown that MIR4773-2 can interact with various small RNA species, including miRNAs and snRNAs. These interactions can alter the expression of downstream genes, potentially leading to the regulation of various cellular processes. For example, several studies have shown that MIR4773-2 can interact with miR-202, a miRNA that is involved in the regulation of various cellular processes.
In addition to its potential as a drug target and biomarker, MIR4773-2 has also generated interest due to its unique structure and biochemical properties. The N-terminal alpha-helicase domain is
Protein Name: MicroRNA 4773-2
The "MIR4773-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4773-2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2
